Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis
Science Advances · 14.03.2025 · 11 (11)
DOI: 10.1126/sciadv.adq4416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 14.03.2025. Verfasst von Cecilia R Chambers und 59 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Ecosystems Program, Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Receptors, Neuropeptide Y, Neuropeptide Y, Signal Transduction. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Pancreatic cancer (PC) is a highly metastatic malignancy. More than 80% of patients with PC present with advanced-stage disease, preventing potentially curative surgery. The neuropeptide Y (NPY) system, best known for its role in controlling energy homeostasis, has also been shown to promote tumorigenesis in a range of cancer types, but its role in PC has yet to be explored. We show that expression of NPY and NPY1R are up-regulated in mouse PC models and human patients with PC. Moreover, using the genetically engineered, autochthonous KP R172H C mouse model of PC, we demonstrate that pancreas-specific and whole-body knockout of Npy1r significantly decreases metastasis to the liver. We identify that treatment with the NPY1R antagonist BIBO3304 significantly reduces KP R172H C migratory capacity on cell-derived matrices. Pharmacological NPY1R inhibition in an intrasplenic model of PC metastasis recapitulated the results of our genetic studies, with BIBO3304 significantly decreasing liver metastasis. Together, our results reveal that NPY/NPY1R signaling is a previously unidentified antimetastatic target in PC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Ecosystems Program, Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, Sydney, New South Wales, Australia.
- School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales (UNSW), Kensington, Sydney, New South Wales, Australia.
- Immune Biotherapies Program, Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
- VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium.
- Translational Oncology Program, Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, Sydney, New South Wales, Australia.
- Data Science Platform, Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia.
ORCID-Profile: Cecilia R Chambers, Supitchaya Watakul, Peter Schofield, Anna E Howell, Daniel A Reed, Kendelle J Murphy, Lily M Channon, Brooke A Pereira, Victoria M Tyma, Victoria Lee, Michael Trpceski, Jake Henry, Pauline Melenec, Max Nobis, Xanthe L Metcalf, Shona Ritchie, Antonia Cadell, Janett Stoehr, Diego Chacon-Fajardo, Jessica L Chitty, Savannah O'Connell, Michael Tayao, Leonard D Goldstein, Angela Connolly, Ben Crossett, Yen T H Tran, Peter Kaltzis, Marija Dinevska, David R Croucher, Robert J Weatheritt, Gonzalo Del Monte-Nieto, Thomas R Cox, Yan-Chuan C Shi, Mark Pinese, Nicola Waddell, Hao-Wen Sim, Tatyana Chtanova, Yingxiao Wang, Anthony M Joshua, Lorraine Chantrill, Anthony J Gill
Zitieren
APA
Chambers, C. R., Watakul, S., Schofield, P., Howell, A. E., Zhu, J., Tran, A. M. H., Kuepper, N., Reed, D. A., Murphy, K. J., Channon, L. M., Pereira, B. A., Tyma, V. M., Lee, V., Trpceski, M., Henry, J., Melenec, P., Abdulkhalek, L., Nobis, M., Metcalf, X. L., …, & Gill, A. J. (2025). Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis. Science Advances, 11(11). https://doi.org/10.1126/sciadv.adq4416
Vancouver
Chambers CR, Watakul S, Schofield P, Howell AE, Zhu J, Tran AMH, et al. Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis. Science Advances. 2025;11(11). doi:10.1126/sciadv.adq4416
BibTeX
@article{Chambers2025,
author = {Chambers, Cecilia R and Watakul, Supitchaya and Schofield, Peter and Howell, Anna E and Zhu, Jessie and Tran, Alice M H and Kuepper, Nadia and Reed, Daniel A and Murphy, Kendelle J and Channon, Lily M and Pereira, Brooke A and Tyma, Victoria M and Lee, Victoria and Trpceski, Michael and Henry, Jake and Melenec, Pauline and Abdulkhalek, Lea and Nobis, Max and Metcalf, Xanthe L and Ritchie, Shona and Cadell, Antonia and Stoehr, Janett and Magenau, Astrid and Chacon-Fajardo, Diego and Chitty, Jessica L and O'Connell, Savannah and Zaratzian, Anaiis and Tayao, Michael and Da Silva, Andrew and Lyons, Ruth J and Goldstein, Leonard D and Dale, Ashleigh and Rookyard, Alexander and Connolly, Angela and Crossett, Ben and Tran, Yen T H and Kaltzis, Peter and Vennin, Claire and Dinevska, Marija and Australian Pancreatic Cancer Genome Initiative (APGI), Australian Pancreatic Cancer Genome Initiative (APGI) and Australian Pancreatic Cancer Matrix Atlas (APMA), Australian Pancreatic Cancer Matrix Atlas (APMA) and Croucher, David R and Samra, Jaswinder and Mittal, Anubhav and Weatheritt, Robert J and Philp, Andrew and Del Monte-Nieto, Gonzalo and Zhang, Lei and Enriquez, Ronaldo F and Cox, Thomas R and Shi, Yan-Chuan C and Pinese, Mark and Waddell, Nicola and Sim, Hao-Wen and Chtanova, Tatyana and Wang, Yingxiao and Joshua, Anthony M and Chantrill, Lorraine and Evans, Thomas R Jeffry and Gill, Anthony J},
title = {Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {11},
doi = {10.1126/sciadv.adq4416}
}
EUVIMED